Clinical Evidence Comparing Wegovy and Mounjaro Dose Schedules
Understanding Wegovy and Mounjaro Equivalent Doses for UK Patients
The question of Wegovy and Mounjaro equivalent doses reflects a fundamental misunderstanding of how these prescription-only medicines work. Wegovy (semaglutide) follows a structured dose escalation from 0.25mg to 2.4mg maintenance over 16 weeks, whilst Mounjaro (tirzepatide) escalates from 2.5mg to 15mg maintenance. These aren't equivalent doses but rather optimal therapeutic levels for each medication's unique mechanism. Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro activates both GIP and GLP-1 receptors simultaneously.
Rather than seeking equivalent doses between Wegovy and Mounjaro, patients should focus on which medication's dosing schedule and mechanism align with their clinical profile. Both treatments require careful titration to minimise gastrointestinal side effects whilst maximising therapeutic benefit. Your prescriber will evaluate factors including your medical history, current medications, and weight management goals to determine the most appropriate treatment pathway. EverydayMeds supports both options through our comprehensive clinical assessment process, ensuring you receive the right medication at the right dose.
Wegovy and Mounjaro Pricing: UK Dose-Specific Costs
When comparing Wegovy and Mounjaro equivalent dose costs, Wegovy's pricing structure reflects its escalating dose schedule. The starter dose (0.25mg) costs £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance dose of 2.4mg (£209.99). Our Intro Trio bundle provides the first three doses (0.25mg, 0.5mg, 1mg) for £299.99, covering your initial 12 weeks of treatment. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25.
Bundle options provide convenience rather than savings, ensuring uninterrupted treatment supply. The Progress Duo (0.5mg & 1mg) costs £189.99, whilst the Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99. Both Wegovy and Mounjaro require ongoing prescription management through our GPhC-registered pharmacy (#9012878), with regular clinical reviews to monitor progress and adjust treatment as needed. Pricing reflects the specialist nature of these prescription-only medicines and includes cold-chain storage and next-day delivery.
Clinical Evidence: Wegovy and Mounjaro Weight Loss Results
The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness in weight management. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 3 demonstrated ~clinically studied weight loss when combined with intensive behavioural therapy, whilst STEP 5 showed sustained ~clinically studied weight loss at two years.
The recent SELECT cardiovascular outcomes trial revealed that Wegovy may reduce major cardiovascular events by 20% in eligible patients, extending beyond weight management benefits. These results shouldn't be directly compared to Mounjaro trials due to different study populations, endpoints, and methodologies. Both medications have demonstrated significant efficacy in clinical settings, but individual responses vary considerably based on adherence, lifestyle factors, and baseline characteristics.
How Wegovy Works: Mechanism Behind the Doses
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your natural incretin hormones. These hormones normally signal fullness after eating and regulate blood glucose levels. By activating GLP-1 receptors in your brain's appetite control centres, Wegovy may reduce hunger signals and increase feelings of satiety after smaller meals. The medication also slows gastric emptying, helping you feel fuller for longer periods. This mechanism explains why dose escalation is crucial—gradually increasing levels allow your body to adjust whilst minimising side effects. The 2.4mg maintenance dose represents the optimal therapeutic level for most patients, though individual responses vary.
Ordering Wegovy: Assessment to Delivery Process
Accessing Wegovy through EverydayMeds begins with our 3-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Your application undergoes review by our qualified prescribers within 3 working days (24-hour express option available). Once approved, your medication ships via next-day delivery using temperature-controlled packaging to maintain the cold chain. Our process ensures compliance with MHRA regulations whilst providing convenient access to this prescription-only medicine. All prescriptions include comprehensive patient information leaflets and injection guidance, supporting safe and effective treatment initiation.
Storage and Practical Considerations for Wegovy Doses
Wegovy requires refrigerated storage at 2-8°C before first use, but offers significant practical advantages over alternatives. Once removed from the fridge, Wegovy pens remain stable for up to 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit. This flexibility proves valuable for UK patients who travel or prefer not to carry cooler packs. The FlexTouch pen design provides accurate, consistent dosing with a simple click mechanism. Each pen contains four doses, supporting the weekly injection schedule throughout your dose escalation and maintenance phases. Proper storage ensures medication potency and treatment effectiveness.
Comparing Wegovy and Mounjaro Dose Schedules for UK Patients
Understanding that Wegovy and Mounjaro equivalent doses don't exist helps clarify treatment selection. Wegovy's dose escalation spans 16 weeks, allowing gradual adaptation to GLP-1 receptor activation. Mounjaro follows a different timeline with its dual receptor mechanism. The choice between treatments depends on your clinical profile, tolerance patterns, and prescriber assessment rather than dose equivalency. Some patients may respond better to single receptor targeting (Wegovy), whilst others benefit from dual pathway activation (Mounjaro).
Both medications require long-term commitment, as weight regain commonly occurs following discontinuation. STEP trial extensions showed patients regained approximately two-thirds of lost weight within one year of stopping treatment. This emphasises that these medications support ongoing weight management rather than providing temporary solutions. Your prescriber can help determine which treatment approach aligns with your long-term health goals and lifestyle factors.
Access Both Wegovy and Mounjaro Through EverydayMeds
Both Wegovy and Mounjaro are available through EverydayMeds, eliminating the need to seek equivalent doses between treatments. Our clinical team evaluates each application individually, considering your medical history, treatment preferences, and specific circumstances. This personalised approach ensures you receive the most appropriate medication and dosing schedule for your situation. Whether you're considering Wegovy's established GLP-1 pathway or Mounjaro's dual receptor approach, our prescribers provide expert guidance throughout your weight management journey. Remember to apply discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout to access our competitive pricing structure.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
